Investigation of Drug–Drug Interactions Between Ritobegron, a Selective β₃‐Adrenoceptor Agonist, With Probenecid in Healthy Men

By  

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 3, 2016-05 ,pp. : 201-207

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effect of mirabegron, a potent and selective β₃-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol

By Krauwinkel Walter   Dickinson James   Schaddelee Marloes   Meijer John   Tretter Reiner   Wetering Jeroen   Strabach Gregory   Gelderen Marcel  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 43-52

Springer Publishing Company

Access to resources Recommend Favorite

Pineal melatonin in rats: suppression by the selective 2 -adrenoceptor agonist medetomidine

By Mustanoja S.M.   Hatonen T.   Johansson-Alila A.   Laakso M.-L.  

European Journal of Pharmacology, Vol. 326, Iss. 2, 1997-05 ,pp. : 229-236

Elsevier

Access to resources Recommend Favorite

Action and Disposition of the β3-Agonist Nebivolol in the Presence of Inflammation; An Alternative to Conventional β1-Blockers

By  

Current Pharmaceutical Design, Vol. 20, Iss. 9, 2014-03 ,pp. : 1311-1317

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of ZD7114, a selective 3 -adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance

By Savontaus E.   Pesonen U.   Rouru J.   Huupponen R.   Koulu M.  

European Journal of Pharmacology, Vol. 347, Iss. 2, 1998-04 ,pp. : 265-274

Elsevier

Access to resources Recommend Favorite